PROCESSA PHARMACEUTICALS INC (PCSA) Stock Overview
USA - NASDAQ:PCSA - US74275C3043 - Common Stock
PCSA Key Statistics, Chart & Performance
The current stock price of PCSA is 0.2103 USD. In the past month the price decreased by -5.95%. In the past year, price decreased by -84.65%.
PCSA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.93 | 702.13B | ||
| JNJ | JOHNSON & JOHNSON | 17.67 | 425.53B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 14.95 | 261.01B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.9 | 238.11B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.97 | 233.65B | ||
| MRK | MERCK & CO. INC. | 10.35 | 199.00B | ||
| PFE | PFIZER INC | 7.11 | 136.96B | ||
| SNY | SANOFI-ADR | 10.4 | 113.17B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.56 | 89.89B | ||
| GSK | GSK PLC-SPON ADR | 8.91 | 80.95B | ||
| ZTS | ZOETIS INC | 22.78 | 62.79B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 51.59 | 47.25B |
Related stock screener links
About PCSA
Company Profile
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. The company is headquartered in Vero Beach, Florida and currently employs 10 full-time employees. The company went IPO on 2013-10-07. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.
Company Info
PROCESSA PHARMACEUTICALS INC
601 21St Street, Suite 300
Vero Beach FLORIDA 21076 US
CEO: David Young
Employees: 10
Phone: 14437763133
PROCESSA PHARMACEUTICALS INC / PCSA FAQ
What is the stock price of PROCESSA PHARMACEUTICALS INC today?
The current stock price of PCSA is 0.2103 USD. The price decreased by -1.87% in the last trading session.
What is the ticker symbol for PROCESSA PHARMACEUTICALS INC stock?
The exchange symbol of PROCESSA PHARMACEUTICALS INC is PCSA and it is listed on the Nasdaq exchange.
On which exchange is PCSA stock listed?
PCSA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PROCESSA PHARMACEUTICALS INC stock?
8 analysts have analysed PCSA and the average price target is 1.02 USD. This implies a price increase of 385.02% is expected in the next year compared to the current price of 0.2103. Check the PROCESSA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PROCESSA PHARMACEUTICALS INC worth?
PROCESSA PHARMACEUTICALS INC (PCSA) has a market capitalization of 10.59M USD. This makes PCSA a Nano Cap stock.
How many employees does PROCESSA PHARMACEUTICALS INC have?
PROCESSA PHARMACEUTICALS INC (PCSA) currently has 10 employees.
What are the support and resistance levels for PROCESSA PHARMACEUTICALS INC (PCSA) stock?
PROCESSA PHARMACEUTICALS INC (PCSA) has a support level at 0.19 and a resistance level at 0.22. Check the full technical report for a detailed analysis of PCSA support and resistance levels.
Should I buy PROCESSA PHARMACEUTICALS INC (PCSA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PCSA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PCSA, evaluating the profitability, health, valuation and growth aspects
- PROCESSA PHARMACEUTICALS INC (PCSA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PROCESSA PHARMACEUTICALS INC (PCSA) Sales and EPS estimates to see what analysts future expectations are.
- PROCESSA PHARMACEUTICALS INC (PCSA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PROCESSA PHARMACEUTICALS INC (PCSA) Insider and Institutional Ownership to learn about the owners and their transactions.
- PROCESSA PHARMACEUTICALS INC (PCSA) Stock Chart to make your own analysis
- PROCESSA PHARMACEUTICALS INC (PCSA) Latest news and press-releases to stay up to date.
Does PROCESSA PHARMACEUTICALS INC (PCSA) stock pay dividends?
PCSA does not pay a dividend.
When does PROCESSA PHARMACEUTICALS INC (PCSA) report earnings?
PROCESSA PHARMACEUTICALS INC (PCSA) will report earnings on 2025-10-28.
What is the Price/Earnings (PE) ratio of PROCESSA PHARMACEUTICALS INC (PCSA)?
PROCESSA PHARMACEUTICALS INC (PCSA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.32).
What is the Short Interest ratio of PROCESSA PHARMACEUTICALS INC (PCSA) stock?
The outstanding short interest for PROCESSA PHARMACEUTICALS INC (PCSA) is 1.29% of its float. Check the ownership tab for more information on the PCSA short interest.
PCSA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PCSA. When comparing the yearly performance of all stocks, PCSA is a bad performer in the overall market: 95.49% of all stocks are doing better.
PCSA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PCSA. While PCSA seems to be doing ok healthwise, there are quite some concerns on its profitability.
PCSA Financial Highlights
Over the last trailing twelve months PCSA reported a non-GAAP Earnings per Share(EPS) of -2.32. The EPS increased by 57.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -157.44% | ||
| ROE | -210.93% | ||
| Debt/Equity | 0 |
PCSA Forecast & Estimates
8 analysts have analysed PCSA and the average price target is 1.02 USD. This implies a price increase of 385.02% is expected in the next year compared to the current price of 0.2103.